AU1908400A - Benzimidazole compounds that are vitronectin receptor antagonists - Google Patents
Benzimidazole compounds that are vitronectin receptor antagonistsInfo
- Publication number
- AU1908400A AU1908400A AU19084/00A AU1908400A AU1908400A AU 1908400 A AU1908400 A AU 1908400A AU 19084/00 A AU19084/00 A AU 19084/00A AU 1908400 A AU1908400 A AU 1908400A AU 1908400 A AU1908400 A AU 1908400A
- Authority
- AU
- Australia
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- benzimidazole compounds
- benzimidazole
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20161198A | 1998-11-30 | 1998-11-30 | |
| US09201611 | 1998-11-30 | ||
| PCT/US1999/026023 WO2000032578A1 (en) | 1998-11-30 | 1999-11-29 | Benzimidazole compounds that are vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1908400A true AU1908400A (en) | 2000-06-19 |
Family
ID=22746536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU19084/00A Abandoned AU1908400A (en) | 1998-11-30 | 1999-11-29 | Benzimidazole compounds that are vitronectin receptor antagonists |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1135374B9 (enExample) |
| JP (1) | JP4480117B2 (enExample) |
| CN (1) | CN1161340C (enExample) |
| AR (1) | AR021427A1 (enExample) |
| AT (1) | ATE338751T1 (enExample) |
| AU (1) | AU1908400A (enExample) |
| CA (1) | CA2353063C (enExample) |
| CO (1) | CO5140112A1 (enExample) |
| DE (1) | DE69933135T2 (enExample) |
| ES (1) | ES2273517T3 (enExample) |
| PE (1) | PE20001427A1 (enExample) |
| WO (1) | WO2000032578A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010112408A (ko) * | 1999-04-07 | 2001-12-20 | 모리타 다카카즈 | N-치환되고-N'-치환된 우레아 유도체 및 TNF-α 생성억제제로서의 그의 용도 |
| PL352367A1 (en) * | 1999-05-17 | 2003-08-25 | Novo Nordisk As | Glucagon antagonists/inverse agonists |
| FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| WO2008148845A2 (en) | 2007-06-07 | 2008-12-11 | Novozymes A/S | Method of preparing a dough-based product |
| EP2595488B1 (en) | 2010-07-21 | 2019-12-04 | Novozymes A/S | Process for preparing a baked product with anti-staling amylase and peptidase |
| WO2015121210A1 (en) | 2014-02-11 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| US9951027B2 (en) | 2014-02-11 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CN104694290A (zh) * | 2014-05-07 | 2015-06-10 | 宁波职业技术学院 | 一种洗脚皂 |
| US10138226B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as MIDH1 inhibitors |
| CN107108554B (zh) | 2014-10-23 | 2020-11-06 | 德国癌症研究中心 | 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑 |
| CA2988356A1 (en) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles as midh1 inhibitors |
| CA2992364A1 (en) | 2015-07-16 | 2017-01-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| AU2021231312A1 (en) | 2020-03-06 | 2022-08-25 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of CDK12 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| BR9508178A (pt) * | 1994-06-29 | 1997-11-18 | Smithkline Beecham Corp | Antagonistas de receptor de vitronectina |
-
1999
- 1999-09-29 CN CN99815842.9A patent/CN1161340C/zh not_active Expired - Fee Related
- 1999-11-29 DE DE69933135T patent/DE69933135T2/de not_active Expired - Lifetime
- 1999-11-29 CA CA002353063A patent/CA2353063C/en not_active Expired - Fee Related
- 1999-11-29 EP EP99962691A patent/EP1135374B9/en not_active Expired - Lifetime
- 1999-11-29 ES ES99962691T patent/ES2273517T3/es not_active Expired - Lifetime
- 1999-11-29 WO PCT/US1999/026023 patent/WO2000032578A1/en not_active Ceased
- 1999-11-29 JP JP2000585220A patent/JP4480117B2/ja not_active Expired - Lifetime
- 1999-11-29 AT AT99962691T patent/ATE338751T1/de not_active IP Right Cessation
- 1999-11-29 AR ARP990106061A patent/AR021427A1/es unknown
- 1999-11-29 AU AU19084/00A patent/AU1908400A/en not_active Abandoned
- 1999-11-30 CO CO99075257A patent/CO5140112A1/es unknown
- 1999-11-30 PE PE1999001198A patent/PE20001427A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000032578A8 (en) | 2002-02-07 |
| ATE338751T1 (de) | 2006-09-15 |
| WO2000032578A1 (en) | 2000-06-08 |
| PE20001427A1 (es) | 2000-12-18 |
| CA2353063C (en) | 2009-06-16 |
| ES2273517T3 (es) | 2007-05-01 |
| CA2353063A1 (en) | 2000-06-08 |
| CN1333755A (zh) | 2002-01-30 |
| CN1161340C (zh) | 2004-08-11 |
| DE69933135D1 (de) | 2006-10-19 |
| DE69933135T2 (de) | 2007-08-09 |
| AR021427A1 (es) | 2002-07-17 |
| JP2002531441A (ja) | 2002-09-24 |
| EP1135374A1 (en) | 2001-09-26 |
| JP4480117B2 (ja) | 2010-06-16 |
| EP1135374B1 (en) | 2006-09-06 |
| EP1135374B9 (en) | 2007-02-21 |
| CO5140112A1 (es) | 2002-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL149872A0 (en) | Substituted imidazole neuropeptide y y5 receptor antagonists | |
| DE69921351D1 (de) | 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii | |
| PL356990A1 (en) | Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists | |
| PL342881A1 (en) | Vitronectin receptor antagonists | |
| AU1908400A (en) | Benzimidazole compounds that are vitronectin receptor antagonists | |
| EG24025A (en) | Vitronectin receptor antagonist | |
| GC0000203A (en) | Vitronectin receptor antagonists | |
| IL141163A0 (en) | Vitronectin receptor antagonists | |
| AU2574801A (en) | Selective iGLUR5 receptor antagonists | |
| AU6051200A (en) | Il-8 receptor antagonists | |
| HK1036065A (en) | Benzimidazole compounds that are vitronectin receptor antagonists | |
| AU5748300A (en) | Il-8 receptor antagonists | |
| AU5168900A (en) | Il-8 receptor antagonists | |
| HK1035319A (en) | Vitronectin receptor antagonists | |
| HK1038180A (en) | Vitronectin receptor antagonists | |
| GB9810182D0 (en) | Vitronectin receptor antagonists | |
| GB9812686D0 (en) | Vitronectin receptor antagonists | |
| GB9810892D0 (en) | Vitronectin receptor antagonists | |
| GB9807384D0 (en) | Vitronectin receptor antagonists | |
| GB9815803D0 (en) | Vitronectin receptor antagonists | |
| GB9807382D0 (en) | Vitronectin receptor antagonists | |
| GB9822331D0 (en) | Vitronectin receptor antagonists | |
| GB9811295D0 (en) | Vitronectin receptor antagonists | |
| GB9810882D0 (en) | Vitronectin receptor antagonists | |
| AU5622400A (en) | Il-8 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |